Dolobid
(Diflunisal)PreclinicalSmall molecule
Dolobid is one of 23 small molecule programs targeting Amyloidosis. It is currently in Preclinical.
1
Indications
4
Total Trials
0
Active Trials
22
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
27 competitors in Amyloidosis
#DrugCompanyPhaseTrials
1Soriatane
GSKApproved
Vyndaqel
KK-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc.
Approved
Decadron
AAspen Global Incorporated
Phase 3
Xeljanz
PPrism Pharmaceuticals
Approved
Darzalex
Johnson & JohnsonPhase 3
Velcade
SShilpa Grover, MD, MPH
Phase 3
Cytoxan
BBaxter Healthcare Corporation
Phase 3
Attruby
NNavire Pharma Inc., a BridgeBio company
Phase 3
Venclexta
AbbViePhase 2
Belamaf
GSKPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
AL amyloidosis1 trial
The Effect of Diflunisal on Familial Amyloidosis
Completed·—·Phase 2/3·NCT00294671·130 enrolled
Regulatory
FDA Approval Timeline[4]
Apr 19, 1982
DOLOBID
NDA NDA018445
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Diflunisal. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]
Details